UK-based RHYTHM AI is to go ahead with a larger clinical trial of its artificial intelligence (AI)-driven system, which could be used as a treatment for atrial fibrillation without the need for medication. Antiarrhythmic drugs are standard therapy but they often only work for around… Read More »RHYTHM AI cleared for large trial of atrial fibrillation mapping tool
Fitbit’s new, $330 smartwatch has a slew of new features, including a wrist-based temperature sensor and a sensor to monitor stress.
What You Should Know: – Eko today announced a global collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart failure. – Through the collaboration, AstraZeneca and Eko will explore accelerating the development of Eko… Read More »AstraZeneca, Eko Collaborate to Advance Innovation Around Heart Failure
What You Should Know: – The National Institutes of Health (NIH) has granted next-generation cardiac AI company Eko an award totaling $2.7 million to support continued collaborative work with Northwestern Medicine Bluhm Cardiovascular Institute – The grant will focus on validating algorithms and help more… Read More »Eko Awarded $2.7M NIH Grant for Heart Murmur & Valvular Heart Disease Detection Algorithms
